|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM16897455X |
003 |
DE-627 |
005 |
20231223120320.0 |
007 |
tu |
008 |
231223s2007 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0563.xml
|
035 |
|
|
|a (DE-627)NLM16897455X
|
035 |
|
|
|a (NLM)17360239
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Takayama, Naoko
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Regulatory role of Peyer's patches for the inhibition of OVA-induced allergic diarrhea
|
264 |
|
1 |
|c 2007
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 26.06.2007
|
500 |
|
|
|a Date Revised 23.04.2007
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Intestinal allergic diseases are initiated by aberrant Th2-type immune responses, including elevation of IgE antibodies (Abs) and infiltration of eosinophils. However, little is known about the role of Peyer's patches (PP) in the control of allergic diseases. Using a mouse model for food allergy, we here show that mice lacking PP are more susceptible to disease development and show higher levels of antigen-specific IgE Abs than do PP-intact mice. In our study, we noted that high numbers of eosinophils infiltrated into the small intestine of PP-null mice. In contrast, the PP of intact mice contained regulatory CD4+CD25+ Foxp3+ T cells (Treg) that are known to produce high levels of IL-10, and inhibited the development of allergic diarrhea. PP-intact mice thus developed allergic diarrhea when treated with anti-CD25 or anti-IL-10 monoclonal antibody (mAb) in vivo. These studies demonstrate that PP, as the site where IL-10-producing Treg cells are created, mediate the mucosal regulatory network for the control of undesired allergic responses in the intestine
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
650 |
|
7 |
|a Interleukin-2 Receptor alpha Subunit
|2 NLM
|
650 |
|
7 |
|a Receptors, Interleukin-7
|2 NLM
|
650 |
|
7 |
|a interleukin-7 receptor, alpha chain
|2 NLM
|
650 |
|
7 |
|a Interleukin-10
|2 NLM
|
650 |
|
7 |
|a 130068-27-8
|2 NLM
|
650 |
|
7 |
|a Immunoglobulin E
|2 NLM
|
650 |
|
7 |
|a 37341-29-0
|2 NLM
|
650 |
|
7 |
|a Ovalbumin
|2 NLM
|
650 |
|
7 |
|a 9006-59-1
|2 NLM
|
700 |
1 |
|
|a Igarashi, Osamu
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kweon, Mi-Na
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kiyono, Hiroshi
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 123(2007), 2 vom: 31. Mai, Seite 199-208
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:123
|g year:2007
|g number:2
|g day:31
|g month:05
|g pages:199-208
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 123
|j 2007
|e 2
|b 31
|c 05
|h 199-208
|